In today’s technology landscape, artificial intelligence (AI) is poised as a transformative force, yet it carries with it a monumental financial challenge. Jessica Wachter, a finance professor at the University of Pennsylvania, has examined the implications of AI investments, particularly those made by hyperscale companies that are constructing vast AI data centers. Instead of predicting how AI models will proliferate, Wachter’s analysis focuses on the necessary growth in earnings these companies must achieve to justify their staggering expenditures, projected to approach one trillion dollars by 2025. Her findings underscore the immense productivity improvements required for AI firms to break even, highlighting the economic stakes of this evolving sector.
Meanwhile, OpenAI is taking proactive steps to enhance AI’s capabilities in the medical field. Recognizing the need for extensive biological data to drive advancements in disease treatment, OpenAI has committed funding to an innovative proposal by policy analyst Ruxandra Teslo. This initiative seeks to leverage data from failed biotechnology firms by participating in bankruptcy proceedings to access valuable regulatory filings and safety data, effectively creating what Teslo refers to as a ‘lost archive’ of biotech information. This strategy aims to supercharge medical AI systems, potentially leading to significant breakthroughs in healthcare and disease management, thereby illustrating the critical intersection of AI and biology in the push for medical advancements.
Source: The Download: AI’s trillion-dollar gamble and OpenAI’s biology data bid via MIT Technology Review